Welcome to our dedicated page for Virax Biolabs Group SEC filings (Ticker: VRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Virax Biolabs Group Limited (VRAX) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, together with AI-generated highlights to help interpret complex disclosures. As a Nasdaq-listed biotechnology company focused on T cell-based diagnostics and immune profiling for viral diseases and post-acute infection syndromes, Virax uses its SEC reports to describe its business focus, clinical programmes, collaborations, governance, and financing activities.
For Virax, current reports on Form 6-K are particularly important. These filings can include information on board and management changes, such as the appointment of independent directors with diagnostics and MedTech experience, and other significant corporate events. They may also reference capital-raising transactions, like private placements of ordinary shares and preferred investment options, or provide additional detail on clinical and regulatory developments that the company has announced in press releases.
Investors interested in capital structure and financing can use the filings page to review disclosures related to private placements, preferred investment options, and agreements to register the resale of securities. These documents often explain how Virax intends to use proceeds, including funding working capital, supporting its ViraxImmune™ clinical studies, and advancing its immune-profiling platform.
Corporate governance information, including changes in directors and committee assignments, is also documented in SEC submissions. For example, Form 6-K reports may outline the resignation of a director, the appointment of a successor, and that individual’s relevant experience in diagnostics and healthcare sectors.
Stock Titan’s interface surfaces AI-powered summaries of Virax’s filings, helping users quickly identify key points such as clinical milestones, regulatory interactions, financing terms, and board changes without reading every page. Real-time updates from EDGAR mean new VRAX filings appear promptly, while dedicated sections for insider and ownership-related disclosures, when filed, allow users to monitor how governance and capital decisions evolve alongside Virax’s work in immunology diagnostics.
Virax Biolabs Group Limited has called its 2025 annual general meeting for March 11, 2026, in Glasgow. Shareholders are being asked to ratify Reliant CPA PC as auditor, re-appoint five current directors, approve a share consolidation, adopt updated governing documents, approve a new equity plan, and authorize potential adjournment.
The proposed share consolidation would combine between 10 and 15 existing ordinary shares into 1 share on or before July 11, 2026, with fractional shares rounded up. This is intended to help the company satisfy Nasdaq’s minimum
The board is also seeking approval of a new 2026 Equity Incentive Plan and UK Sub-Plan reserving 2,000,000 ordinary shares for awards. Existing 2022–2024 plans cover smaller pools, much of which is already granted. The board unanimously recommends voting “FOR” all six proposals.
Virax Biolabs Group Limited has filed a resale registration covering up to 25,875,000 ordinary shares for existing investors. These shares are issuable from a December 2025 private placement and consist of 12,500,000 shares from Pre-Funded Warrants, 12,500,000 shares from Preferred Investment Options, and 875,000 shares from Placement Agent Warrants. As of December 17, 2025, Virax had 7,423,432 ordinary shares outstanding.
Virax is an emerging growth immunology-focused biotechnology company developing T cell diagnostics and immune profiling tools, including its in-development ViraxImmune™ assay and ImmuneSelect research-use-only portfolio. In the related private placement with Armistice Capital, Virax raised approximately $5,000,000 in gross proceeds and issued long-dated, low-priced warrants and options. The selling shareholders will receive all proceeds from resales, while Virax may receive additional cash only if these warrants and options are exercised.
FAQ
What is the current stock price of Virax Biolabs Group (VRAX)?
What is the market cap of Virax Biolabs Group (VRAX)?
